NO20082288L - Monoklonalt anti-ADDL-antistoff og anvendelse derav - Google Patents
Monoklonalt anti-ADDL-antistoff og anvendelse deravInfo
- Publication number
- NO20082288L NO20082288L NO20082288A NO20082288A NO20082288L NO 20082288 L NO20082288 L NO 20082288L NO 20082288 A NO20082288 A NO 20082288A NO 20082288 A NO20082288 A NO 20082288A NO 20082288 L NO20082288 L NO 20082288L
- Authority
- NO
- Norway
- Prior art keywords
- addl
- types
- antibodies
- disease
- monoclonal anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
SAMMENDRAG Den foreliggende oppfinnelsen vedrører antistoffer som differensielt gjenkjenner multidimensjonale konformasjoner for AP-avledede diffunderbare ligander, også kjent som ADDL-typer. Antistoffene ifølge oppfinnelsen kan skille mellom hjerneekstrakter med Alzheimers sykdom og humane kontrollhjerneekstrakter og er nyttige i fremgangsmåter for å påvise ADDL-typer og å diagnostisere Alzheimers sykdom. De foreliggende antistoffene blokkerer også binding av ADDL-typer til nevroner, sammensetning av ADDL-typer og taufosforylering og er derfor nyttige fremgangsmåter for forebygging og behandling av sykdommer som er assosiert med løselige oligomerer av amyloid ß1-42.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2005381125 | 2005-10-21 | ||
PCT/US2006/040508 WO2007050359A2 (en) | 2005-10-21 | 2006-10-17 | Anti-addl monoclonal antibody and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20082288L true NO20082288L (no) | 2008-05-19 |
Family
ID=39671607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20082288A NO20082288L (no) | 2005-10-21 | 2008-05-19 | Monoklonalt anti-ADDL-antistoff og anvendelse derav |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1940466B1 (no) |
JP (1) | JP5289963B2 (no) |
CN (1) | CN101291692A (no) |
AU (1) | AU2006306553B9 (no) |
CA (1) | CA2626783A1 (no) |
NO (1) | NO20082288L (no) |
RU (1) | RU2008120027A (no) |
WO (1) | WO2007050359A2 (no) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
CA2631195C (en) | 2005-11-30 | 2016-04-05 | Abbott Laboratories | Monoclonal antibodies against amyloid beta protein and uses thereof |
CN101432302A (zh) | 2005-11-30 | 2009-05-13 | 艾博特公司 | 抗-Aβ球聚体抗体,其抗原结合部分,相应的杂交瘤、核酸、载体、宿主细胞,生产所述抗体的方法,包含所述抗体的组合物,所述抗体的应用以及使用所述抗体的方法 |
EP2325209A3 (en) | 2006-03-23 | 2011-08-03 | BioArtic Neuroscience AB | Improved protofibril selective antibodies and the use thereof |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
US8323654B2 (en) | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
US7931899B2 (en) | 2007-05-14 | 2011-04-26 | Medtronic, Inc | Humanized anti-amyloid beta antibodies |
PE20090766A1 (es) * | 2007-06-12 | 2009-07-09 | Ac Immune Sa | Anticuerpo igg1 humanizado |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
CA2701793C (en) | 2007-10-05 | 2017-04-25 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
EP2586797A3 (en) * | 2007-11-27 | 2013-07-24 | Medtronic, Inc. | Humanized anti-amyloid beta antibodies |
WO2009079566A2 (en) | 2007-12-18 | 2009-06-25 | Acumen Pharmaceuticals, Inc. | Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production |
CA2733782A1 (en) * | 2008-08-14 | 2010-02-18 | Merck Sharp & Dohme Corp. | Methods for purifying antibodies using protein a affinity chromatography |
KR101531949B1 (ko) | 2009-12-11 | 2015-06-26 | 아라클론 바이오테크, 에스.엘. | 아밀로이드 베타 펩티드의 개선된 검출 방법 및 시약 |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9320793B2 (en) | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
EP2593475B1 (en) * | 2010-07-14 | 2016-03-02 | Merck Sharp & Dohme Corp. | Anti-addl monoclonal antibody and uses thereof |
US9176151B2 (en) | 2010-07-14 | 2015-11-03 | Acumen Pharmaceuticals, Inc. | Antibodies, kit and method for detecting amyloid beta oligomers |
SG187173A1 (en) | 2010-07-30 | 2013-02-28 | Ac Immune Sa | Safe and functional humanized anti beta-amyloid antibody |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
US20140302532A1 (en) | 2011-04-12 | 2014-10-09 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
RU2014105172A (ru) * | 2011-07-13 | 2015-08-20 | Мерк Шарп И Доум Корп. | Способ обнаружения олигомеров бета-амилоида в образце жидкости организма и варианты его применения |
JP6231263B2 (ja) * | 2012-07-17 | 2017-11-15 | 株式会社島津製作所 | アフィニティ支持体及びそれを用いた物質の捕捉方法 |
CN106661103B (zh) | 2014-07-10 | 2020-11-03 | 生命北极神经科学公司 | 改进的Aβ初原纤维结合抗体 |
WO2018156180A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0683234B2 (en) * | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antibody against beta-amyloid or their derivative and use thereof |
US5786180A (en) * | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
US20030068316A1 (en) * | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
DK0994728T3 (da) * | 1997-04-09 | 2008-12-01 | Intellect Neurosciences Inc | Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf |
JP2006508072A (ja) * | 2002-10-01 | 2006-03-09 | ノースウエスタン ユニバーシティ | アミロイドベータ由来拡散性リガンド(ADDLs)、ADDL代替物、ADDL結合性分子、およびそれらの使用 |
PE20050627A1 (es) * | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
US7780963B2 (en) * | 2004-10-25 | 2010-08-24 | Merck & Co., Inc. | Anti-ADDL antibodies and uses thereof |
-
2006
- 2006-10-17 CA CA002626783A patent/CA2626783A1/en not_active Abandoned
- 2006-10-17 CN CNA2006800392637A patent/CN101291692A/zh active Pending
- 2006-10-17 RU RU2008120027/13A patent/RU2008120027A/ru not_active Application Discontinuation
- 2006-10-17 WO PCT/US2006/040508 patent/WO2007050359A2/en active Application Filing
- 2006-10-17 EP EP06836346A patent/EP1940466B1/en active Active
- 2006-10-17 JP JP2008536730A patent/JP5289963B2/ja active Active
- 2006-10-17 AU AU2006306553A patent/AU2006306553B9/en not_active Expired - Fee Related
-
2008
- 2008-05-19 NO NO20082288A patent/NO20082288L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2007050359A8 (en) | 2008-05-08 |
JP2009519895A (ja) | 2009-05-21 |
JP5289963B2 (ja) | 2013-09-11 |
EP1940466A4 (en) | 2010-04-07 |
AU2006306553B9 (en) | 2011-09-29 |
EP1940466B1 (en) | 2012-11-28 |
EP1940466A2 (en) | 2008-07-09 |
RU2008120027A (ru) | 2009-11-27 |
CA2626783A1 (en) | 2007-05-03 |
CN101291692A (zh) | 2008-10-22 |
WO2007050359A2 (en) | 2007-05-03 |
WO2007050359A3 (en) | 2007-06-21 |
AU2006306553B2 (en) | 2011-08-25 |
AU2006306553A1 (en) | 2007-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20082288L (no) | Monoklonalt anti-ADDL-antistoff og anvendelse derav | |
NO20072700L (no) | Anti-ADDL antistoffer og anvendelser derav | |
MX2022005782A (es) | Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos. | |
MX2009012950A (es) | ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS. | |
MX2009012949A (es) | Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos. | |
LUC00053I9 (fr) | Anticorps diriges contre cd38 pour le traitement du myelome multiple | |
MX338421B (es) | Anticuerpos fosfoespecificos que reconocen la proteina tau. | |
WO2010115843A3 (en) | Pharmaceutical composition | |
MA45655A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MX354662B (es) | Anticuerpos fosfoespecificos que reconocen la tau. | |
MX2007013626A (es) | Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos. | |
MX338640B (es) | Anticuerpo monoclonal anti-ligando difundible derivado de amiloide beta y usos de los mismos. | |
WO2005018424A3 (en) | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits | |
TR201800669T4 (tr) | Alzheimer hastaliğinda tau-aracili patoloji̇ni̇n tanilanmasi ve protei̇n bazli tedavi̇si̇ | |
WO2007062245A3 (en) | Human monoclonal antibody human cd134 (ox40) and methods of making and using same | |
WO2006014638A3 (en) | ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS | |
DE60336848D1 (de) | Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz | |
AR083819A1 (es) | UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL | |
EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
MX2021011715A (es) | Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención. | |
WO2008051326A3 (en) | Identification of contactins and l1- cams as ligands for the amyloid precursor protein | |
EA201290671A1 (ru) | Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р | |
EA200702634A1 (ru) | Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения | |
WO2010024927A3 (en) | Treatment of amyloidoses using myelin basic protein and fragments thereof | |
WO2004047854A3 (en) | Methods for the treatment of alzheimers disease and compositions therefore |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |